What the FDA labels say about taking them together
Levodopa and rasagiline
Rasagiline's FDA label of June 30, 2020 names levodopa in its warnings and precautions section; levodopa's label does not name rasagiline itself but warns about its class (MAO inhibitors). The rasagiline label: “Decreasing the levodopa dose may lessen or eliminate this side effect May cause hallucinations and psychotic-like behavior May cause impulse control/compulsive behaviors May cause withdrawal-emergent hyperpyrexia and …”
Check it at the source: the levodopa FDA label on DailyMed (effective July 20, 2026, Merz Pharmaceuticals, LLC); the rasagiline FDA label on DailyMed (effective June 30, 2020, Teva Pharmaceuticals USA, Inc.).
What does the levodopa label say about rasagiline?
Levodopa's label does not name rasagiline itself; it warns about its class (MAO inhibitors):
Levodopa label, contraindicationsCONTRAINDICATIONS INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor.
Levodopa label, drug interactionsOxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4) ].
Source: FDA drug label (Inbrija), Merz Pharmaceuticals, LLC, effective July 20, 2026 (SPL set 077c0f39-a3a2-4b2b-a184-09131889dcfb), via openFDA; the full label on DailyMed
What does the rasagiline label say about levodopa?
Rasagiline label, warnings and precautionsDecreasing the levodopa dose may lessen or eliminate this side effect ( 5.7 ) May cause hallucinations and psychotic-like behavior ( 5.8 ) May cause impulse control/compulsive behaviors ( 5.9 ) May cause withdrawal-emergent hyperpyrexia and confusion
Source: FDA drug label (Rasagiline), Teva Pharmaceuticals USA, Inc., effective June 30, 2020 (SPL set e802c83c-e581-4a11-b83d-1df47120078d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Levodopa | Rasagiline | |
|---|---|---|
| Labeled for | Parkinson's disease | Parkinson's disease |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.521 per tablet 0.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once